IDSA GUIDELINES Bundle (free trial)

Aspergillosis 2016

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/57608

Contents of this Issue

Navigation

Page 17 of 23

17 Treatment Table 1. Summary of Recommendations for the Treatment of Aspergillosis (cont'd) Condition Therapy Invasive syndromes of Aspergillus Primary Alternative Comments Empirical and preemptive antifungal therapy For empirical antifungal therapy: • Liposomal AmB (3 mg/kg/day IV) • Caspofungin (70 mg day 1 IV and 50 mg/day IV thereafter) or micafungin (100 mg/day IV) • Micafungin (100 mg/day IV) • Voriconazole (6 mg/kg IV every 12 h for 1 day, followed by 4 mg/kg IV every 12 h. Oral therapy can be used at 200–300 mg every 12 h or 3–4 mg/kg q12h) Preemptive therapy is a logical extension of empirical therapy in a high risk population with evidence of invasive fungal infection (e.g., pulmonary infiltrate or positive GM assay result). Prophylaxis against IA Posaconazole: • Oral suspension: 200 mg TID • Tablet: 300 mg BID on day 1, then 300 mg daily • IV: 300 mg BID on day 1, then 300 mg daily • Voriconazole (200 mg BID) • Itraconazole suspension (200 mg PO every 12 h) • Micafungin (50–100 mg/day IV) or caspofungin (50 mg/day IV) Efficacy of posaconazole prophylaxis demonstrated in high-risk patients (patients with GVHD and neutropenic patients with AML or MDS) Saprophytic or colonizing syndromes of Aspergillus Primary Alternative Comments Aspergilloma No therapy or surgical resection Itraconazole or voriconazole; similar to IPA • The role of medical therapy in the treatment of aspergilloma is uncertain. • Penetration into preexisting cavities may be minimal for AmB.

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Aspergillosis 2016